We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Diagnosis of AFP-negative early-stage hepatocellular carcinoma using Fuc-PON1.
Discovery Medicine 2017 March
Our previous study demonstrated that Fuc-PON1 (the ratio of fucosylated serum paraoxonase 1 to the total serum serum paraoxonase 1) was increased significantly in hepatocellular carcinoma (HCC) patients with low AFP levels. Herein, a separate cohort of AFP-negative (AFP- ) early HCC patients was studied to validate the diagnostic potential of Fuc-PON1. Aleuria aurantia lectin (AAL) ELISA and protein ELISA were measured simultaneously to calculate PON1 fucosylation at its protein level. Lens culinaris agglutinin reactive AFP (AFP-L3) and glypican-3 (GPC3) concentrations of the same specimens were also evaluated. The AUC was 0.78 (95% CI 0.704 to 0.852) for Fuc-PON1, with sensitivity of 62.2%, specificity of 67.7%, and accuracy of 64.5%. However, concentration alterations of AFP-L3 and GPC3 in AFP- HCC patients were not remarkable. The results of the present study provided confirmed evidences for clinical application of Fuc-PON1, which demonstrated its superior diagnosis potential for distinguishing AFP- early HCC from AFP- liver cirrhosis (LC) patients.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app